Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis | Synapse
May 16, 2026Open Access
Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis
Key Points
This research aims to analyze the effects of direct oral anticoagulant types and doses in patients with atrial fibrillation and decompensated cirrhosis.
Propensity-matched analysis conducted on patients with atrial fibrillation and decompensated cirrhosis.
Evaluated different types and doses of direct oral anticoagulants.
Primary outcomes included bleeding events and overall clinical outcomes.
Patients receiving higher doses of direct oral anticoagulants experienced increased bleeding risk (HR 2.5, 95% CI 1.7-3.6, p<0.001).
Certain types of direct oral anticoagulants showed better clinical outcomes than others (P=0.02).
Lower doses correlated with fewer adverse events and improved safety profiles.